Annual report pursuant to Section 13 and 15(d)

Other Balance Sheet Details - Contingent Liabilities (Details)

v3.6.0.2
Other Balance Sheet Details - Contingent Liabilities (Details) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]      
Revenue royalty payable on all Cydex-related revenue (percent) 20.00%    
Cydex-related revenue amount that triggers royalty payments $ 15,000,000.0    
Additional revenue royalty payable when higher threshold of Cydex-related revenue met (percent) 10.00%    
Cydex-related revenue amount that triggers additional royalty payments $ 35,000,000.0    
Contingent Liability [Roll Forward]      
Commercial rights, beginning 13,500,000 $ 15,200,000  
Payments (8,777,000) (6,740,000) $ (3,493,000)
Fair Value Adjustment 3,400,000 5,000,000  
Commercial rights, ending 8,100,000 13,500,000 15,200,000
CyDex      
Contingent Liability [Roll Forward]      
Commercial rights, beginning 9,500,000 11,497,000  
Payments (6,158,000) (5,848,000)  
Fair Value Adjustment 3,259,000 3,800,000  
Commercial rights, ending 6,600,000 9,500,000 11,497,000
Metabasis      
Contingent Liability [Roll Forward]      
Commercial rights, beginning 4,000,000 3,652,000  
Payments (2,618,000) (865,000)  
Fair Value Adjustment 74,000 1,172,000  
Commercial rights, ending $ 1,500,000 $ 4,000,000 $ 3,652,000